Today: 16 June 2026
Browse Category

NASDAQ:AXSM 3 November 2025 - 2 January 2026

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

Axsome Therapeutics shares surged 22.9% to $182.64 on Dec. 31 after the FDA accepted its AXS-05 filing for Alzheimer’s disease agitation and set an April 30, 2026 target action date. The company also said it plans to submit an NDA for AXS-12 in narcolepsy in January, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
2 January 2026
·
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome Therapeutics shares surged 22.9% to $182.64 after the FDA granted priority review to its application for AXS-05 in treating agitation in Alzheimer’s disease, setting an April 30 decision date. The company also plans to file for approval of AXS-12 for cataplexy in narcolepsy this month, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
1 January 2026
··
AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

Axsome Therapeutics shares closed at $151.20 on Monday, near record highs, after reporting 63% year-over-year revenue growth in Q3 2025 to $171 million. The stock has climbed over 50% in the past year, valuing the company at about $7.6 billion. Net loss for the quarter narrowed to $47.2 million, or –$0.94 per share. Trading volume on Monday was roughly 540,000 shares.
25 November 2025
·

Stock Market Today

  • Nasdaq Steady Amid Oil Drop Ahead of Federal Reserve Decision
    June 15, 2026, 8:21 PM EDT. The Nasdaq rose 3.07% and the S&P 500 gained 1.65% on Monday, boosted by easing oil prices and potential U.S.-Iran deal developments reducing geopolitical risk. Oil dropped near $83 a barrel, lifting stocks sensitive to fuel costs such as airlines and tech shares. The Dow hit a new all-time high. Investors now await the Federal Reserve's June 16-17 meeting, where policymakers are expected to hold interest rates steady at 3.50%-3.75%. Market focus centers on Fed Chair Kevin Warsh's post-meeting remarks for policy clues amid persistent inflation concerns. The subdued after-hours futures suggest cautious sentiment ahead of the Fed's statement, as cheaper energy and geopolitical calm offer relief to stocks but risks remain.

Latest articles

Nasdaq steady in late trading as oil eases, Fed up next

Nasdaq steady in late trading as oil eases, Fed up next

16 June 2026
U.S. stocks soared Monday as falling oil prices and a preliminary U.S.-Iran deal fueled a relief rally, with the Nasdaq up 3.07%, S&P 500 up 1.65%, and Dow closing at a record high; after-hours futures dipped slightly as investors awaited Wednesday’s pivotal Federal Reserve decision and Chair Kevin Warsh’s first post-meeting press conference.
Intel stock gains after BofA upgrade, foundry business in focus

Intel Gains as Chip Shares Recover

16 June 2026
Intel surged to $127.86, topping analyst targets, as chip stocks rallied on easing inflation and AI optimism, but the stock’s gains outpace consensus expectations and recent earnings remain negative; investors now await the unconfirmed July 23 earnings report for proof that demand is driving real revenue growth.
Dave & Buster’s falls after Q1 comes up short, comps slip

Dave & Buster’s falls after Q1 comes up short, comps slip

16 June 2026
Dave & Buster’s shares plunged 4.72% to $12.32, then dropped another 11.2% after hours, after Q1 revenue, adjusted profit, and comparable-store sales all missed expectations; management’s guidance for positive sales trends and free-cash-flow remains the next key catalyst as investors weigh the company’s turnaround credibility.
Go toTop